Hospital

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses how patients were selected for the phase 2 trial assessing niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses how SGO shapes and guides the direction of medical researchers and health care professionals in the gynecologic oncology field.

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.

The death rate from cervical cancer has dropped by more than 50% since 1975.

Factors such as economic stability and education access can be categorized into social determinants of health.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Pharmacy leadership remaining mindful, connected, and engaged is crucial to support the mental health needs of their staff.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses the design of the phase 2 trial assessing niraparib in patients with stage III, stage IV, or platinum-sensitive recurrent uterine serous carcinoma.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the future of the pharmacist on the gynecologic oncology patient care team.

Black women are at an increased risk of dying from cancer of any type compared to White women, but gynecologic cancers have some of the widest survival gaps.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.

Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.

Marina Frimer, MD, FACOG, FACS, gynecologic oncologist at the Northwell Health Cancer Institute, discusses her presentation at the Society of Gynecologic Oncology 2022 annual meeting on the phase 2 trial of maintenance niraparib in patients with stage 3, stage 4, or platinum-sensitive recurrent uterine serous carcinoma.

Moderna seeks EUA for its Spikevax COVID-19 vaccine for a fourth booster dose in individuals 18 years of age and older who have received an initial booster of any authorized or approved COVID-19 vaccine.

Aerosolized hydrogen peroxide system added to current hospital infection prevention protocols found to significantly reduce cases of Clostridioides difficile infection.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses the role of the pharmacist in gynecologic oncology patient care and treatment.

Best practices call for referring to resources, such as those from HHS and the University of Liverpool.

Shannon Hough, director of ClinReview and Clinical Content for McKesson, discusses the advantages of including pharmacy staff as part of the care team when payer or drug availability challenges arise.

Making the process to order a screening for hepatitis C virus easier improved screenings from 42% to approximately 80%.

Encorafenib in combination With anti-EGFR monoclonal antibody improves overall survival.

Olaparib (Lynparza) was found to significantly improve overall survival in patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer.

Michael Abrams, MPH, PhD, senior health researcher at Public Citizen’s Health Research Group, discusses actions needed to help manage the opioid epidemic in the country.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

Patients may not admit or recognize when they have a brain injury, but pharmacists can be a valuable resource.

The KEYLYNK-010 trial was evaluating a combination of pembrolizumab (Keytruda) and olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer who progressed following chemotherapy and either abiraterone acetate (Zytiga) or enzalutamide (Xtandi).

This month's generic product news features lanreotide injections, glycopyrrolate oral solution, and vasopressin.

Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.

The median survival time of patients was 12 months compared with 7 in the control group, the analysis demonstrates.